Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

NCT07220135 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Carboplatin
DRUG: Docetaxel
DRUG: Trastuzumab (or biosimilar)
DRUG: Pertuzumab (or biosimilar)

Sponsor

University of Kansas Medical Center